Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation by unknown
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The  in  vivo observation  that  infiltrates of lymphocytes and  monocytes are 
present in  tissues  undergoing both normal and pathological fibrosis has led to 
the in vitro investigation of the role played by mononuclear cells in regulating 
fibroblast functions (1-6).  These studies indicate that activated T  lymphocytes 
and  monocytes/macrophages can  effectively modulate several fibroblast  func- 
tions through the release of soluble macromolecular factors, collectively catego- 
rized as lymphokines (LK) j and monokines (MK). LK and MK preparations have 
been  found  to  have activities  both  as  stimulators  and  inhibitors  of fibroblast 
movement (7-9), proliferation (10-14),  and protein production, including pro- 
duction of fibrosis-forming collagens (14-18).  The relationships of these fibro- 
blast-regulating factors  to  known  immunoregulatory LK  and  MK are  largely 
undetermined, except that studies indicate that  interleukin  1 is the fibroblast 
growth-stimulating MK and fibronectin the fibroblast-chemotactic MK (11, 8). 
We and others (12-15,  17,  18)  have recently shown that human peripheral 
blood mononuclear cells activated with T cell mitogens, like concanavalin A (Con 
A), or monocyte activators, like lipopolysaccharide (LPS), produce, respectively, 
LK  in  the 50,000  Mr range and  MK in  the  20,000  Mr range that  inhibit  the 
growth and collagen production of cultured dermal fibroblasts. Since Con A  is 
known to stimulate T  lymphocytes to produce 3' interferon (IFN-3") (which has a 
reported gel filtration M,. of 50,000) and LPS stimulates monocytes/macrophages 
to produce IFN-c~//3 of 20,000 Mr,  we investigated whether LK/MK inhibition 
of fibrob/ast proliferation or collagen production could be attributed to human 
IFN (19-21).  Our results suggest that the LK and MK which inhibit fibrob/ast 
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collagen  production  are  IFN-y  and  IFN-/~,  respectively,  and  that  those  early 
acting LK and  MK which inhibit fibroblast proliferation are not IFN. 
Materials and  Methods 
lnterferons.  Human recombinant IFN-a2 (SCH 30500; sp act, 1.2 ×  10 s U/rag protein) 
from Escherichia coli was kindly supplied by Schering Corporation, Kenilworth, N  J; human 
recombinant E. coli-derived IFN-3, (1.3  ×  10  7 U/mg protein) was a gift from Genentech 
Inc., South San Francisco, CA. Research grade samples of naturally derived human IFN- 
(2  x  106 U/mg) and IFN-3" (1  ×  106 U/rag) were obtained from Meloy Laboratories, 
Inc., Springfield, VA. Naturally derived human IFN-B (2 ×  105 U/mg) was obtained from 
Lee Biomolecular, Inc., San Diego, CA. The titer of these IFN samples ranged from 6.6 
×  10 ~ to 2.1  ×  105 U/ml and they were added directly to fibroblast cultures after dilution 
to the desired concentrations with culture media. 
Anti-IFN Antibodies.  Polyclonal rabbit antibodies to human IFN-a were obtained from 
Meloy Laboratories (titer, 2 ×  104 neutralizing U/ml) and Interferon Sciences, Inc., New 
Brunswick, NJ (1  ×  105 U/ml). Polyclonal rabbit antibody to human IFN-/3 (5 ×  104 U/ 
ml)  was  fi~om Lee  Biomolecular,  Inc.  Both  polyclonal  goat  and  monoclonal  murine 
antibodies to human IFN-3, (2 ×  104 U/ml) were obtained from Meloy Laboratories, Inc. 
Neutralization studies were performed by incubating samples of LK and MK preparations 
with the desired concentration of anti-IFN antibody at 37 °C for 1 h before being added 
to fibroblast cultures or submitted to antiviral assay. 
Interferon Antiviral Assay.  Analysis of the antiviral activity of LK and MK preparations 
was performed by Lee Biomolecular, Inc. using a cytopathic effect inhibition assay with 
diploid foreskin fibroblasts and encephalomyocarditis virus. The assay is a duplicate, serial 
endpoint quantitation and has a resolution of ~<30%. Antiviral activity was standardized 
against NIH human IFN-leukocyte and IFN-3' reference reagents and expressed as units 
per milliliter. 
Production of LK and MK Supernatants Inhibiting Fibroblast Growth and Collagen Produc- 
tion.  Supernatants were prepared from the human peripheral blood mononuclear cells 
recovered from Ficoll-Hypaque gradients as previously described (14).  Briefly, mononu- 
clear ceils (2  ×  106/ml) were incubated in endotoxin-free Dulbecco's minimum essential 
medium containing  25  mM  Hepes and  2  mM glutamine (DMEM)  (M.  A.  Bioproducts, 
Walkersville, MD) supplemented with 0.5%  human serum albumin (Travenol Laborato- 
ries, Inc., Glendale, CA) and stimulated with 12.5 ug/ml Con A (Sign~a Chemical Co., St. 
Louis, MO) or 20 ug/ml LPS (E. coli 0128:B12; Sigma Chemical Co.) to produce LK and 
MK supernatants, respectively. Cell-free supernatants were collected after 72 h incubation 
and exhaustively dialyzed against distilled  water containing 0.01%  thiodyglycol (Sigma 
Chemical Co.) before being dialyzed against fresh DMEM and assayed. Con A-induced 
supernatants  were  assayed  in  the  presence  of  25  mM  a-methyl-D-mannoside (Sigma 
Chemical Co.). 
Preparation  of LK and MK Gel Filtration  Fractions.  Enriched LK and MK fractions of 
supernatants were prepared by gel filtration on  Sephacryl S-200 (Pharmacia, Inc., Pis- 
cataway, N  J) eluting with phosphate-buffered saline containing 0.01% polyethylene glycol 
6000  and  0.01%  thiodyglycol, as  described  previously (14).  LK activity eluted  in  the 
50,000 M, range and MK activity in the 20,000 M, range. 
Fibroblast Cultures.  Primary cell cultures were established from skin explants taken 
from a normal neonatal foreskin and from a sample of normal adult facial skin removed 
during cosmetic surgery. The fibroblasts were grown to confluency in RPM I 1640 medium 
containing penicillin (100 U/ml), streptomycin (100 gg/ml), 2 mM glutamine, and  10% 
heat-inactivated fetal calf serum (FCS) (M. A. Bioproducts) and subcultured after trypsin- 
ization. Fibroblasts were used between the 3rd and 10th passages. 
Assay for Activity Inhibiting Fibroblast Proliferation.  Assay of fibroblast growth-inhibit- 
ing activity was performed  using  subconfluent  fibroblast microcultures  (Microtest  III: 
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were first plated at 3,000 fibroblasts per microwell in  100 ~1 of DMEM plus 10% FCS for 
18 h at 37°C in a 5% CO2 atmosphere to permit adherence to microwell bottoms. After 
18 h adherence, medium was removed and dilutions of LK or MK preparations or IFN 
in  200  #1  fresh  DMEM  plus  10%  FCS  were added  to the fibroblast cultures  for 24  h, 
along with 0.5 #Ci of [3H]thymidine (25 Ci/mmol; Amersham Corp., Arlington Heights, 
II.). After 24 h incubation,  fibroblasts were harvested and [~H]thymidine incorporation 
quantitated as reported (14).  Briefly, after medium aspiration, cultures were trypsinized, 
harvested onto glass fiber filters using an automated harvester, and lysed by washing with 
distilled water. The [~H]thymidine-labeled DNA that was trapped by the glass fiber filters 
was counted  using  liquid  scintillation  spectrometry.  [3H]Thymidine incorporation  into 
DNA has been shown to be a true correlate of fibroblast growth by several investigators 
(10,  11,  14). 
Assay  for Activity Inhibiting Fibroblast Collagen Production.  Trypsinized fibroblasts were 
plated at 20,000 fibroblasts per well in  100 #1 DMEM plus 10% FCS for 18 h at 37°C in 
a  5%  CO2  atmosphere  to  produce  a  confluent  monolayer of adherent  fibroblasts,  as 
described  previously (14).  After  adherence,  medium  was  removed and  replaced  with 
DMEM plus I% FCS and incubated for an additional 48 h to allow fibroblasts to achieve 
proliferative quiescence. The medium was then removed and replaced with 200 #1 fresh 
DMEM plus  1% FCS containing 50 ug/ml ascorbic acid and various dilutions of LK or 
MK preparations or IFN and incubated for an additional 48 h. Cultures were labeled with 
0.5 uCi of[3H]proline (31 Ci/mmol; Amersham Corp.) and 50/~g/ml ~-aminopropionitrile 
for the  final  24  h  of culture.  The [3H]proline  incorporation  into pepsin-resistant, salt- 
precipitated extracellular collagen was determined as previously described (14, 22).  The 
inclusion  of/3-aminopropionitrile ensures  that :>90%  of the  collagen  produced  will  be 
secreted into the culture medium (23). 
Assay  for Activity Effecting Fibroblast Total Noncollagenous Protein Production.  The effect 
of LK or MK preparations and IFN on noncollagenous protein production was assayed 
using culture conditions identical to those described for the assay of inhibition of collagen 
production, except fibroblasts were cultured in Ham's F10 medium which contains a low 
level of tryptophan, and labeled with 0.5 ~zCi [3H]tryptophan (28.7 Ci/mmol; New England 
Nuclear, Boston, MA) instead of [3H]proline, since tryptophan is not present in collagen 
(24). At the termination of culture, supernatant medium was removed from the fibroblast 
cell  layer and  the cell  layer digested  in  0.5  N  NaOH.  [3H]Tryptophan-labeled protein 
contained in the cell digest and supernatant medium was precipitated with 7.5% tricblo- 
roacetic acid  (TCA).  The  precipitates  were  collected  onto  glass  fiber  filters  using  an 
automated harvester, and washed, dried, and counted using liquid scintillation spectrom- 
etry. 
Results 
Titering and IFN Typing of Antiviral Activity  Contained  in LK and MK Prepara- 
tions.  Since  the  mode  of  induction  and  the  M,.  estimates  of  our  fibroblast- 
inhibiting  LK and  MK  suggested  that  they  could  be  IFN,  we  determined  the 
antiviral titers of our LK and  MK preparations (Table I). A  representative Con 
A-induced  supernatant contained an antiviral titer equivalent to  1,000  U/ml of 
NIH  reference  IFN-3,,  while  an  LPS-induced  supernatant  contained  2,300  U/ 
ml.  Moreover, neutralization  of supernatant  antiviral activity with specific anti- 
IFN antibodies indicated that Con A  supernatants contained only IFN-3, and no 
IFN-c~ or -/3. LPS supernatants contained primarily IFN-/3, since anti-IFN-/3 almost 
entirely blocked antiviral activity. The partial block of LPS supernatant  activity 
by anti-IFN-a is probably the artifactual result of the 30% accuracy limits of the 
assay, since the  20,000  M,. fractions that could contain  both  IFN-a and -/3 were 
only inhibited  by anti-IFN-/3. Con  A  supernatants  thus contain  IFN-3,, and  LPS DUNCAN  AND  BERMAN  519 
TABLE  I 
Antiviral Titer and Type of lFN Contained in LK and MK 
Supernatants and Column Fractions 
Sample 
IFN Titer* 
Neutralization with Anti-IFN  * 
Anti-  Anti-  Anti- 
IFN-c~  IFN-~  IFN-'y  § 
U/ml  U/ml 
Con A-induced supernatant  !  1,000  1,000  1,000  <1.8 
50,000 Mr fraction  330  250  250  <1.8 
LPS-induced supernatant  2,300  1,500  16  2,300 
20,000 M~ Fraction  450  480  10  420 
* Titer listed is normalized to NIH human IFN-~" reference reagent. 
¢ Samples neutralized with 2,000 neutralizing U/ml anti-lFN. 
§ Anti-IFN-y was a murine monoclonal antibody. 
u Supernatants were assayed neat, and M, fractions as 1:10 dilutions. 
supernatants contain IFN-/3,  and chromatography provides no further enrich- 
ment for these IFN. Similar results were obtained when LK and MK preparations 
were referenced against an NIH human IFN-leukocyte reagent: LPS supernatant 
contained 290  U/ml and Con A supernatant,  180  U/ml. Unstimulated control 
supernatants contained <1.8  U/ml  reference  IFN-3,  or  <0.2  U/ml  reference 
IFN-leukocyte.  Thus,  our  LPS-induced  MK  preparations  appear  to  contain 
principally IFN-~, and our Con A-induced LK preparations, IFN-3". 
Effect oflFN on Fibroblast Proliferation.  IFN of all types and degrees of purity 
have been reported (25)  to inhibit the proliferation of a  variety of tumor and 
trans~brmed  cell  lines,  as  well  as  normal  cells  in  culture,  including  human 
fibroblasts. We investigated whether samples of natural and recombinant DNA- 
derived IFN-~, -t3, and -3'  could inhibit the proliferation of normal adult and 
neonatal dermal fibroblasts cultured under conditions optimal for growth inhi- 
bition by our LK and MK preparations (14).  Under these subconflue,  n't culture 
conditions (Fig.  1 and Table II), recombinant-derived IFN-o~2 and -3" at concen- 
trations from 10 to  l0 s U/ml, and naturally derived IFN-/3 at  10 to 104  U/ml, 
did not inhibit normal fibroblast proliferation, while LK and MK preparations 
containing  1,000-2,000  U/ml  IFN  caused  inhibitions  of >_50%. Samples  of 
naturally derived IFN-o~ and -3' were also ineffective inhibitors of proliferation 
at 10 to 105 U/ml (data not shown). Previous studies (26) have also reported that 
IFN  do  not  inhibit  human  fibroblast  growth  during  the  first  24  h  of IFN 
treatment of asynchronized subconfluent cultures similar to  those  used here. 
Such cultures required  48-72  h  of IFN  treatment to demonstrate significant 
inhibition of growth (26).  We also observed that at least 48-72 h  of treatment 
was required  to  inhibit  fibroblast growth.  96  h  treatment with  l0 s  U/ml  of 
recombinant IFN-ol2 or -3' or natural IFN-/3 caused a growth inhibition of foreskin 
fibroblasts of 66, 56, and 57%, respectively. After 96 h of treatment, the growth 
of cultures treated with LK or MK preparations were still inhibited to the same 
degree  as  observed  after  24  h  of treatment (data  not  shown). These  results 
suggest  that  our  LK and  MK  preparations  contained  two  growth-inhibiting 520  INTERFERONS  INHIBIT  FIBROBLAST  COLLAGEN  PRODUCTION 
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FIGURE  1.  Concentration-dependent inhibition of foreskin fibroblast collagen production by 
1FN. Cultures of normal foreskin fibroblasts were incubated with increasing concentrations of 
recombinant DNA-derived IFN-a~ (©), purified naturally derived IFN-/3 (ZX), or recombinant 
DNA-derived IFN-3' (e), and fibroblast proliferation (broken lines) and collagen production 
(solid  lines) determined  as  described  in  Materials  and  Methods.  Values are  reported  as  a 
percentage of untreated control cultures (100%) and each point represents the mean of three 
separate experiments of triplicate determinations with interexperimental SEM being <10%. 
components: the fibroblast growth-inhibiting  LK and MK (14), which are early 
acting and not IFN, and IFN-3, and -/3, which are late-acting inhibitors. 
Effect of lFN on Fibroblast Collagen Production.  Samples of natural and recom- 
binant-derived IFN-a, -/3, and -3" were assayed for inhibition of collagen produc- 
tion  using  fibroblast  culture  conditions  similar  to  those  we  have  previously 
determined  (14)  to  be  optimal  for  LK/MK-mediated  inhibition  of  collagen 
production.  Under  these  low serum,  confluent  culture  conditions,  stationary- 
phase  fibroblasts  are  sensitive  to  agents  that  effect  collagen  production  but 
unresponsive to growth-modulating signals. This permits the selective assessment 
of collagen  production-inhibiting  activity.  As  shown  in  Fig.  1  and  Table  I1, 
recombinant IFN-a2 and -3' and natural  IFN-/3 caused concentration-dependent 
inhibitions  of collagen production  by both adult and neonatal  fibroblast micro- 
cultures. Samples of naturally derived IFN-c~ and -3" gave inhibitions very similar 
to those shown for recombinant  IFN-c~2 and -3". At concentrations  _>10  ~ U/ml, 
all IFN samples inhibited fibrob/ast collagen production by _>50%. These data, 
which present IFN strength in antiviral  units per milliliter, suggest that IFN-c~, - 
/3, and -3" differ in potency as collagen production  inhibitors.  However, if IFN 
are compared on a molar basis, IFN-a, -8, and -3' are approximately equipotent 
inhibitors of collagen production.  Molar comparison  of IFN takes into account DUNCAN  AND  BERMAN  521 
TABLE  II 
Inhibition of Adult Dermal Fibroblast Collagen Production by IFN 
and LK and MK Preparations 
Inhibition of  Units per  Inhibition of 
milliliter  proliferation*  collagen 
production* 
None  8,708 +- 430  3,490 ±  171 
Recombinant IFN-c~2  10 ~  8,682 +- 726  1,472 ±  153 
104  8,676 + 780  1,741  + 201 
l0  s  7,938 +  141  1,841  ±  193 
10 ~  7,548 + 750  2,541  ±  212 
Natural I FN-/3  104  8,222 +- 472  1,285 ±  52 
l0  s  7,830 + 470  1,373 ±  161 
102  8,176 +- 482  2,275 ±  147 
Recombinant 1FN-7  10 ~  7,162 + 978  897 + 48 
104  7,511  -  729  1,047 +- 153 
l0  s  7,536 --. 558  1,254 ___ 80 
102  7,602 +- 604  1,750 +- 98 
Con A-induced supernatant  ~ 
50,000 M, fraction 
3,047  + 482  1,096 "4- 44 
2,177"-_381  1,211  "--98 
LPS-induced supernatant  3,982 _  268  1,884 +- 109 
20,000 Mr fraction  4,789 +  511  2,078 _  215 
Representative experiment showing the effect of IFN and LK and MK 
preparations on  the  proliferation and  collagen production  of adult 
dermal fibroblasts cultured as described in Materials and Methods. Data 
was confirmed in one additional experiment. 
* Counts per minute +_ SD of triplicate determinations of [3H]thymidine 
incorporation into DNA. 
* Counts  per minute  ±  SD  of triplicate determinations of [SH]proline 
incorporation into collagen. 
Supernatants were assayed at a dilution of 1:2, and Mr fractions at 1:4. 
the  fact  that  the  antiviral  specific activity of pure  IFN-3,  is  generally  ~10-fold 
lower (---2 ×  107  U/mg  protein) than  IFN-a or -/3 (22  x  108  U/mg  protein), and 
thus yields a more meaningful comparison of I FN collagen production-inhibiting 
activities. Together  with the results in Table  I, these findings suggest that  IFN- 
3'  is  the  component  of our  LK  preparations  that  inhibits collagen  production, 
while IFN-/3 is the inhibitor in our MK preparations. Furthermore,  the magnitude 
of inhibition induced by the LK and MK preparations correlates with the antiviral 
IFN titer of each. 
Effect  of IFN  and  LK  and  MK  Preparations  on  Total  Noncollagenous  Protein 
Production.  To demonstrate  that the observed inhibition of collagen production 
by  IFN,  LK,  and  MK  was  not  due  to  a  general  toxic  effect  or  a  nonspecific 
suppression of total protein  synthesis, we investigated the effect of these agents 
on  the  incorporation  of [SH]tryptophan  into protein.  [SH]Tryptophan  incorpo- 
ration into TCA-precipitable  material in a  discriminating assay for total noncol- 
lagenous protein synthesis, since tryptophan  is not present in collagen molecules 
(24).  In  an  assay of parallel fibroblast cultures  labeled with  [SH]tryptophan  by 522  INTERFERONS  INHIBIT  FIBROBLAST  COLLAGEN  PRODUCTION 
TCA precipitation  or collagen assay (Materials and Methods), <1%  of the [3H]- 
tryptophan-labeled protein assayed as collagen.  Neither I FN (102-105 U/ml) nor 
LK or MK preparations (Table III) inhibited the production of total noncollag- 
enous proteins present in the cell layer and supernatant medium of adult dermal 
fibroblasts.  Moreover,  IFN-3' and LK preparations caused a marked increase in 
the production of total noncollagenous proteins in the cell layer and supernatant 
medium. The 1FN-q,-induced increase may represent the induction of cell surface 
HLA-DR antigen and its shedding into the medium (27,  28).  Results similar to 
those  in  Table  III  were  also  obtained  using neonatal  foreskin  fibroblasts  and 
naturally derived  IFN-a and -3, (data not shown).  Thus,  inhibition  of collagen 
production is not due to a general  toxic effect of IFN, LK, or MK on fibroblast 
protein synthesis. 
Effect of Anti-IFN on LK/MK-mediated Inhibition  of Fibroblast Proliferation  and 
Collagen  Production.  To  further  demonstrate  that  the  collagen  production- 
inhibiting activity of our LK and MK preparations was due to the IFN-y content 
of our LK preparations and IFN-fl in our MK preparations,  we assayed LK and 
TABLE  Ill 
Effect of lFN and LK and MK Preparations on Total Noncollagenous Protein Production by 
Adult Dermal Fibroblasts 
Units per 
milliliter 
[SH]Tryptophan incorporation 
Media*  Cell layer* 
None 
Recombinant  IFN-a~ 
Natural IFN-¢/ 
Recombinant  IFN-y 
7,483 ___ 806  35,791  -+ 1,481 
105  6,884 +  353  38,545 -  5,029 
l04  8,081  --- 241  42,765 +  4,004 
103  7,931  +  597  41,854 4- 2,735 
102  7,707 +  973  42,192 -  2,747 
104  6,330 --- 352  32,504 +  2,194 
l0 s  7,068 -+  176  39,250 4- 599 
103  7,019 +  999  38,726 4- 3,535 
l05  20,378 +  1,857  99,411  4- 10,713 
104  19,630 +  662  89,413 4- 8,399 
l0 s  17,478 _+  1,193  89,408 4- 3,583 
10  2  15,162 +  1,133  74,127 4- 2,567 
Con A-induced supernatant§  12,899 4-  1,523  76,198 4- 3,452 
50,000 Mr fraction  14,257 4- 726  74,755 4- 3,447 
LPS-induced supernatant  7,628 4-  1,487  39,770 -+ 4,523 
20,000 M~ fraction  7,879 4- 798  40,657 +  5,335 
Representative  experiment  showing  the  effect  of  1FN  and  LK  and  MK  preparations  on  total 
noncollagenous  protein production  by confluent adult dermal  fibroblasts cultured as described in 
Materials and Methods.  Data was confirmed in one additional experiment. 
* Counts per minute 4- SD of triplicate determinations of [3H]tryptophan-labeled protein precipitated 
from fibroblast culture media by TCA. 
* Counts per minute 4- SD of triplicate determinations of [3H]tryptophan-labeled protein precipitated 
fi'om digested fibroblast cell layer by TCA. 
Supernatants were assayed at a dilution of 1:2, and M,. fi'actions at  1:4. DUNCAN  AND  BERMAN  523 
MK preparations for inhibiting activity in the presence of anti-IFN antibodies. 
The collagen production-inhibiting activity of Con A-induced supernatant and 
its 50,000 Mr fraction was completely suppressed (Table IV) by 103 neutralizing 
U/ml  of monoclonal antibody to  IFN-3,, while polyclonal antibodies to  IFN-~ 
and -~ had no effect.  A  polyclonal anti-IFN-~, similarly suppressed LK collagen- 
inhibiting activity  (data  not  shown).  The  collagen-inhibiting activity  of  LPS- 
induced MK supernatant and its 20,000 M~ fraction was suppressed by polyconal 
anti-IFN-~ but not by anti-lFN-~ or -7- When tested alone, none of the anti-IFN 
significantly affected  collagen production of control fibroblast cultures. These 
data  confirm that  collagen production-inhibiting LK  and  MK  are  IFN-3, and 
IFN-/3,  respectively.  The  data  in Table  IV  also  indicate that  anti-IFN do  not 
neutralize the  proliferation-inhibiting  activities exerted by  LK and  MK prepa- 
rations after 24 h  of treatment; thus, the early-acting growth-inhibiting LK and 
MK are not IFN. 
TAnLE  IV 
Selective Neutralization  of LK and MK Inhibition  of Foreskin 
Fibroblast Collagen Production by Anti-IFN 
Inhibition  of col-  Inhibition  of 
proliferation*  lagen produc- 
tion* 
Con A-induced supernatant  *  41 +-- 8  42 + 9 
Plus anti-lFN-c~  §  36 -+ 12  39 + 4 
Plus anti-IFN-B  47 _+ 7  30 -  9 
Plus anti-lFN-3,  44 -  3  102 +  14 
50,000 Mr fraction  30 +  10  40 +-- 3 
Plus anti-IFN-c~  37 + 5  36 --- 7 
Plus anti-IFN-B  30 + 7  46 +  16 
Plus anti-IFN-.y  39 + 8  94 +  12 
LPS-induced supernatant  54 -  5  49 + 6 
Plus anti-IFN-c~  60 +- 12  52 + 3 
Plus anti-IFN-B  47 +_ 2  92 -4- 10 
Plus anti-IFN-'y  53 +_ 9  63 _+ 18 
20,000 Mr fraction  43 _+ 6  56 +-. 9 
Plus anti-lFN-c~  40 +_ 13  60 _-. 11 
Plus anti-lFN-~  48 +_ 11  96 _+ 8 
Plus anti-IFN-3,  41 + 4  58 + 2 
Data shows the effects of anti-lFN antibodies on the proliferation and 
collagen production-inhibiting  activities of LK or MK preparations on 
foreskin fibroblasts as detailed in Materials and Methods. 
* Values are reported as a percentage of untreated control cultures (100%) 
and each  value represents the mean +  SEM of three separate  experi- 
ments of triplicate determinations. 
Supernatants were used at a dilution of 1:2, and Mr fractions at 1:4. 
§ Anti-lFN were  used  at  a  final  concentration of  1,000  neutralizing 
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Discussion 
Fibrosis is a normal reparative process that occurs after tissue injury. In normal 
repairs, like wound healing, fibroblasts infiltrate the damaged area, proliferate, 
and synthesize the components of the connective tissue matrix, including proteo- 
glycans and collagens. This restructuring of tissue with connective tissue results 
in scar formation, and fibrosis is terminated. Recent studies (7-18) indicate that 
mononuclear cells of the immune system may play an  important role both  in 
initiating  and  terminating  fibrosis,  through  the  release  of LK  and  MK  that 
stimulate or inhibit fibroblast functions. Of the LK and MK that may terminate 
fibrosis, those which inhibit fibroblast proliferation and collagen production have 
been the most extensively studied and characterized (12-15,  17,  18).  Because 
these LK and MK share similar methods of induction and biochemical charac- 
teristics with IFN, we have investigated if these LK and MK inhibiting activities 
could be attributed to human IFN. 
To ensure that our LK and MK preparations did indeed contain IFN, we first 
assayed them for antiviral activity and IFN type. The results (Table I) show the 
Con A-induced LK supernatants contained 1,000 U/ml of IFN-3` but no IFN-c~ 
or -ft. LPS-induced MK supernatants contained almost 2,300 U/ml of, primarily, 
IFN-/3, no IFN-3,,  and perhaps low levels of IFN-c~. The selective induction of T 
lymphocyte-derived IFN-3' by Con A and of macrophage-derived IFN-/3 by LPS 
have been previously reported (19,  20).  Samples of purified, naturally derived 
IFN-c~, -/3, and  -3'  and  recombinant  DNA-derived  IFN-o~2 and  -3"  were  then 
assayed for inhibition of proliferation and collagen production by both neonatal 
and adult dermal fibroblasts. 
We  have  previously shown  (14)  that  LK  and  MK  preparations  inhibit  the 
growth of nonconfluent, asynchronous fibroblast  cultures after only  24  h  of 
treatment. The tested IFN,  however, caused no inhibition of fibroblast prolif- 
eration after 24 h of treatment and, in fact, required 48-72 h of treatment for 
significant inhibition  of DNA synthesis.  The delayed action of IFN  was likely 
due to the fact that they do not directly inhibit DNA synthesis by cells in the S 
phase but prevent cells from entering the S-phase by blocking or prolonging the 
G0/Gl  and G2 phases  (25,  29).  The early action of LK and  MK preparations 
suggests that they may directly inhibit  DNA synthesis by cells in  the S phase. 
This difference between the kinetics of LK/MK- and IFN-induced inhibition of 
fibroblast growth, and our additional experiments showing that anti-IFN anti- 
bodies do not block the early-acting, growth-inhibiting activities of LK or MK 
preparations, suggest that such activities are caused by factors distinct from IFN. 
The  aberrant  production  of these  early-acting,  growth-inhibiting  factors  by 
patients with progressive systemic sclerosis (PSS) suggests they play an important 
role in terminating normal fibrosis (14). 
IFN did mimic LK/MK action, however, by inhibiting the collagen production 
of confluent, steady-state fibroblast  cultures.  During the course of this  study, 
others (30, 31) reported that purified, naturally derived IFN-c~ and -3` as well as 
recombinant-derived IFN-~xa and  -3`  inhibited  fibroblast  collagen  production. 
Our  results  confirm and  extend these  reports  to  show that  all  types of IFN, DUNCAN  AND  BERMAN  525 
including IFN-/3, inhibit collagen production. Moreover, our results demonstrate 
that the collagen production-inhibiting activity of LK preparations was selec- 
tively blocked by anti-IFN-3` and MK activity was blocked by anti-IFN-13,  sug- 
gesting  that  collagen  production-inhibiting  LK  and  MK  are  IFN-3`  and  -B, 
respectively. 
From the present study, it is impossible to determine the mechanism by which 
IFN inhibit collagen production, but a previous report (30) suggests that IFN-3` 
acts at the transcriptional  level by inhibiting collagen mRNA synthesis.  IFN-~ 
and -/3 may act similarly but some studies suggest that they may be acting via 
increased  prostaglandin  production,  since  indomethacin  blocks  the  effect of 
macrophage-derived (18) but not T  lymphocyte-derived (17) inhibitors of col- 
lagen production. 
Our results, identifying IFN-a, -/3, and -3" as inhibitors of fibroblast collagen 
production and of late, but not early, fibroblast proliferation, suggest that IFN 
may be the mediators which terminate immunologically induced fibrosis. Further 
investigations are needed to  determine the  role  IFN  play  in  normal  fibrotic 
repair  and  whether IFN  production  by  mononuclear cells  or  IFN  action  on 
fibroblasts are altered in pathological fibrosis. Although IFN production and the 
action of purified or recombinant IFN on fibroblasts have yet to be studied in 
any fibrotic disease, the production and action of collagen production-inhibiting 
LK and MK have been studied in PSS.  These studies show that normal levels of 
collagen production-inhibiting LK and MK (IFN-3" and -/3) are produced by PSS 
patients (14) and that dermal fibroblasts grown from PSS subjects are sensitive 
to LK (IFN-3")-mediated inhibition of collagen production (32). Although ruling 
out deficient IFN production as a causative factor in PSS, these studies suggest 
that PSS may be amenable to therapy with IFN or IFN inducers. Similarly, other 
diseases characterized by excessive fibrosis, such as idiopathic puhnonary fibrosis, 
liver cirrhosis, chronic graft-vs.-host disease, localized scleroderma, and keloid 
formation,  may  also  be  responsive  to  IFN  treatment  whether  or  not  their 
etiologies involve decreased production of or response to IFN. 
Summary 
Human  peripheral  blood  mononuclear cells activated with  concanavalin  A 
(Con A) or lipopolysaccharide (LPS) produce, respectively, lymphokines (LK) of 
50,000 M, or monokines (MK) of 20,000 Mr that inhibit the growth and collagen 
production of cultured human dermal fibroblasts.  Because antigenic typing of 
the antiviral activity of these LK and MK preparations revealed that LK contained 
mainly 3' interferon (IFN-3"), and MK, primarily IFN-/3, we investigated if any of 
the fibroblast-inhibiting activities could be attributed to human IFN. Unlike LK 
and MK, which act within 24 h  to inhibit the growth of subconfluent foreskin 
and adult dermal fibroblasts, samples of purifed, natural derived IFN-~, -/3, and 
-3' and recombinant DNA-derived IFN-o~2 and -3' were ineffective inhibitors at 
24 h and required 48-72 h to significantly inhibit growth. However, all IFN did 
mimic LK/MK action in causing concentration-dependent inhibition of collagen 
production  by  confluent fibroblast  microcultures.  Furthermore,  the  collagen 
production-inhibiting activity of Con A-induced LK supernatant and its 50,000 526  1NTERFERONS  INHIBIT FIBROBLAST  COLLAGEN  PRODUCTION 
M,-  fraction  was  completely  suppressed  by  103  neutralizing  U/ml  of  either 
polyclonal or monoclonal antibody to IFN-3,, while polyclonal antibodies to IFN- 
a  and -/3 had no effect. Similarly, the collagen production-inhibiting  activity of 
LPS-induced  MK  supernatant  and  its  20,000  M,  fraction  was  suppressed  by 
polyclonal  anti-IFN-/3 but  not  by anti-IFN-a  or  -3'.  Anti-IFN  failed  to  reverse 
early-acting LK or MK growth-inhibiting activities.  These data suggest collagen 
production-inhibiting  LK and  MK are IFN-3, and IFN-/3, respectively, and that 
early acting, growth-inhibiting  LK and MK are not IFN. 
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derived IFN-~2. 
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